Recurrent invasive high-grade mucoepidermoid carcinoma of the larynx and hypopharynx is a rare occurrence. These tumors have been commonly associated with salivary gland tumors, most commonly the parotid gland. The patient usually presents with the following symptoms: hoarseness (if larynx is involved), or changes in voice character, sore throat, cough, odynophagia, dysphagia, otalgia, difficulty breathing, weight loss, lymphadenopathy. Here we present a case of a recurrent invasive high-grade mucoepidermoid carcinoma of larynx and hypopharynx. The patient was a 67-year-old male that originally presented in 2006. At that time he underwent a wide field laryngectomy, right thyroid lobectomy, and biopsy of the right digastric node. He was a clinical stage III, pT3N0M0. No adjuvant radiation therapy was given at that time. The patient remained asymptomatic until February 2014, when he presented with dysphagia and neck swelling. Positron emission tomography/computed tomography showed evidence of recurrence. The patient was treated with definitive intensity modulated radiation therapy (IMRT) with concurrent chemotherapy. Treatment for this disease is gathered by scattered case reports. If surgery is a possibility it is considered as first line therapy. Post-surgical radiation is then offered. However, in this case the recurrent tumor was located near the carotid artery, and thus surgery was not a possibility. Therefore, concurrent chemotherapy and radiation with IMRT and weekly cis-platinum was given. While the optimum combination of treatment has not yet been established because of the rarity of this cancer's location site, the current patient appeared to have an excellent response from the definitive IMRT and chemotherapy treatment.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4935825 | PMC |
http://dx.doi.org/10.4081/rt.2016.6204 | DOI Listing |
J Clin Med
December 2024
Radiation Oncology Department, Osakidetza, Donostia University Hospital, 20014 San Sebastian, Spain.
(1) : Salivary gland tumors (SGTs) are a rare and diverse group of neoplasms arising in the parotid, submandibular, sublingual, and minor salivary glands distributed throughout the upper aerodigestive tract. Given the rarity and complexity of MSGTs, understanding their epidemiology across diverse populations is crucial for improving diagnostic and therapeutic strategies. (2) : A retrospective analysis involving 45 patients diagnosed with malignant salivary gland tumors and treated with curative intention between 1 July 2016 and 1 July 2021 in a tertiary academic hospital was performed.
View Article and Find Full Text PDFSci Rep
January 2025
Department of Oral and Maxillofacial Surgery, National Center for Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Research Center of Oral Biomaterials and Digital Medical Devices& Beijing Key Laboratory of Digital Stomatology & NHC Key Laboratory of Digital Stomatology & NMPA Key Laboratory for Dental Materials, Peking University School and Hospital of Stomatology, Beijing, China.
Biological processes intricately intertwine with tumorigenesis, significantly influencing treatment outcomes and prognosis. However, the mechanisms fostering mucoepidermoid carcinoma (MEC) remain inadequately elucidated. This research utilizes expression profiles of lncRNAs from clinical MEC tissues and matched normal glandular tissues, integrating public data to explore the biological mechanisms and immune microenvironment characteristics of tumorigenesis.
View Article and Find Full Text PDFBMC Cancer
January 2025
Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Background: Malignant salivary gland tumors (SGTs) present diagnostic challenges and limited treatment options. This study aims to determine the proportion of malignant SGTs overexpressing the androgen receptor (AR) by immunohistochemistry (IHC) and its association to age, sex, anatomical site, histopathological subtype and grade which may inform customized treatment approaches.
Methodology: This was a retrospective cross-sectional analytical study of archived paraffin embedded tissue blocks of malignant SGTs diagnosed at MNH Central Pathology Laboratory (CPL) from January 2019 to December 2022.
Biotech Histochem
January 2025
Department of Ear Nose and Throat, Firat University Faculty of Medicine, Elazig, Turkey.
This study explores the role of irisin and interleukins in parotid tumors by determining the tissue staining intensity of irisin, the salivary and plasma levels of irisin, and the plasma levels of IL-4, IL-6, IL-10 and TNF-alpha in individuals with parotid tumors. Forty-eight patients and forty healthy individuals were included to the study and allocated into four group. Benign Group I (pleomorphic adenoma), Group II (Warthin's tumor), Group III (mucoepidermoid carcinoma) and Group IV (benign parotid control group, healthy control group).
View Article and Find Full Text PDFMedicina (Kaunas)
December 2024
King Abdulaziz Medical Center, National Guard Health Affairs, Riyadh 21423, Saudi Arabia.
Salivary gland tumors (SGTs) are diverse lesions with varying morphological and clinical characteristics. Limited data exist on the distribution of SGTs in Saudi Arabia. We aimed to fill this gap by examining the distribution of SGTs across four tertiary hospitals in Riyadh.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!